Jun 14, 2019
Reistone Announces First Patient Dosed in Two Phase II Global Studies of SHR0302 JAK Inhibitor for Ulcerative Colitis and Crohn's Disease
Jun 03, 2019
Ulcerative Colitis: Epidemiology Forecast to 2026 - Update
May 17, 2019
Crohn's & Colitis UK and Ampersand Health Partner to Create Innovative App to Help People With Crohn's and Colitis
May 16, 2019
Takeda to Highlight Compelling New Data and Portfolio Advances for Gastrointestinal (GI) Diseases at DDW 2019
May 14, 2019
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019
May 09, 2019
Immunic, Inc. to Participate in Upcoming May Conferences
May 08, 2019
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
Apr 11, 2019
InDex Pharmaceuticals Provides Status Update on the Patient Recruitment in the CONDUCT Study
Mar 26, 2019
Prime Therapeutics finds biologic therapy accounts for vast majority of Crohn's disease, ulcerative colitis total cost of care
Mar 18, 2019
Understanding Pediatric Chronic Illnesses
Feb 11, 2019
Bridge Biotherapeutics Presented Preclinical and Phase I Study Results for BBT-401 at the Crohn's & Colitis Congress
Jan 21, 2019
Navigating the Obstacles of Disease Treatment
Jan 18, 2019
New Online Resource from AGA and the IBD Parenthood Project, in Collaboration with Multidisciplinary Experts, Provides Guidance and Dispels Fears About Pregnancy for Women with IBD
Dec 11, 2018
Government of Canada joins GoHere washroom access program
Dec 06, 2018
Oshi Health Expands #1 IBD Mobile App Into Canada, Denmark, and the United Kingdom
Nov 27, 2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
Nov 12, 2018
Crohn's & Colitis Foundation Review of the Role of Medical Cannabis in the Management of Crohn's and Colitis Published in IBD Journal
Nov 12, 2018
The First Pellino-1 Inhibitor BBT-401 Confirms Its Safety and Tolerability from the Phase I Study
Oct 23, 2018
Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis
Oct 10, 2018
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018